Nicotine
Drugs Used In Nicotine Dependence
Sold as NIQUITIN MINIS · Habitrol Step 3 · Kirkland Signature Quit 2
- Drug class
- Drugs Used In Nicotine Dependence
- Availability
- Over-the-counter
- Routes
- Transdermal, Oral, Buccal
- Markets covered
- 2
- Products on record
- 120
- FDA reports (12 mo)
- 1,628
Overview
Plain-language summary, compiled from the cited regulatory records
Nicotine is a medication used to aid in smoking cessation [1]. It belongs to the drug class of drugs used in nicotine dependence [1]. Nicotine is approved to reduce withdrawal symptoms, including nicotine craving, that are associated with quitting smoking [1].
This active ingredient is available under various brand names, including Habitrol Step 3 and Kirkland Signature Quit 2 [1]. In the past 12 months, there have been 1628 adverse event reports related to nicotine products [2]. The most frequently reported reactions include the drug being ineffective, issues with product usage technique, problems with product adhesion, nausea, and off-label use [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 60 | May 20, 2026 |
| GB United Kingdom | MHRA | 60 | May 29, 2026 |
USUnited States· FDA
60 products
Uses
Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking
How to take
GBUnited Kingdom· MHRA
60 products
Uses
Relief of nicotine withdrawal symptoms, in nicotine dependency as an aid to smoking cessation. The 4 mg strength is used when severe withdrawal symptoms are experienced. Patient counselling and support normally improve the success rate.
How to take
Drug interactions
Known interactions involving Nicotine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 10ece1fa-f4c2-42… · revised May 2, 2025 [PDF]
- [2]MHRA (UK) · PL085530795 · revised September 12, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.